Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...

At Recursion's recent [Learnings] Call, Co-Founder and CEO Chris Gibson welcomed investors and analysts to share exciting updates on the company's progress in decoding biology to change the way drugs ...

Stock analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued on Thursday. The firm set a “buy” rating on the biotechnology ...

Equities researchers at StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report issued on Thursday. The brokerage set a “buy” rating on the stock. MEI Pharma ...